Corporate News Update: Zhejiang Jiuzhou Pharmaceutical
Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (ticker 603456.SS) closed the trading session on Wednesday, 21 October 2026, with its shares unchanged at 0 % relative to the previous close. At the close, a single share was priced at approximately CNY 16.83 on the Shanghai Stock Exchange. The company’s market capitalization stands at CNY 14.8 billion, with 875.5 million shares outstanding. In the past 24 hours, the trading volume amounted to roughly CNY 292 million.
Since the end of the previous month, the share price has risen by 3.7 %. The 200‑day simple moving average is positioned at CNY 14.88. Historically, the 52‑week high reached CNY 22.25 on 17 November 2025, while the 52‑week low fell to CNY 12.05 on 11 June 2026.
Recent Corporate Actions
Zhejiang Jiuzhou Pharmaceutical has recently announced a third‑quarter earnings briefing, reaffirming its commitment to transparent investor communication. The company has also completed a share‑repurchase programme, buying back stock at market‑determined prices. Proceeds from the repurchase are earmarked for employee‑share plans and potential corporate incentives. This move reflects a broader industry trend of capital optimisation and shareholder‑value enhancement, as well as a strategic effort to support the share price, retain talent, and manage the capital structure in a competitive sector.
The latest disclosures underline the company’s focus on financial health and stakeholder engagement, consistent with its long‑term operational objectives.
Market Context: Comparable Peer Performance
| Stock | Ticker | 24‑hour Change | Current Price (CNY) | Market Cap (CNY bn) | Notes |
|---|---|---|---|---|---|
| Zhejiang Publishing & Medi | 601921.SS | 0 % | 7.88 | 17.6 | P/E 13.34 |
| Col Global | 300364.SZ | 0 % | 24.64 | 17.7 | Positive outlook for 2026; AI‑driven growth |
| Henan Huanghe Whirlwind | 600172.SS | 0 % | 12.21 | 17.8 | – |
| Wuxi Nce Power | 605111.SS | 0 % | 42.25 | 17.7 | P/E 57.34 |
| Betta L | 300558.SZ | 0 % | 42.05 | 17.7 | P/E 37.47; recent trial setback for DURAVYU |
The peer group has exhibited flat performance over the past 24 hours, mirroring Zhejiang Jiuzhou Pharmaceutical’s unchanged trajectory. Notably, Betta L’s recent announcement of a failed Phase III trial for its eye‑care drug DURAVYU may influence its short‑term valuation dynamics.
Company Profile
Zhejiang Jiuzhou Pharmaceutical operates in the pharmaceutical sector from its headquarters in Taizhou, China. The firm specialises in the development, production, and sale of active pharmaceutical ingredients and intermediates. Its product portfolio spans central nervous system agents, non‑steroidal anti‑inflammatory drugs, anti‑infective agents, and hypoglycaemic medications. Further information regarding its offerings and strategic initiatives can be found on the company’s website at www.jiuzhoupharma.com .
This article presents a concise overview of Zhejiang Jiuzhou Pharmaceutical’s recent trading activity, corporate actions, and peer comparison within the broader market context.
